BioSpace News Archive

Tryp Therapeutics, Inc. today announced it has received confirmation from the U.S. Food and Drug Administration that its review of Tryp’s Investigational New Drug #163,994 is complete and that the Company may proceed with its Phase 2a clinical trial at Massachusetts General Hospital (MGH) investigating the effects of psilocybin-assisted psychotherapy in the treatment of patients aged 21+ suffering from Irritable Bowel Syndrome (IBS).

TheracosBio announced that Brenzavvy™, an FDA-approved oral sodium-glucose cotransporter 2 inhibitor, is now available by prescription through the Mark Cuban Cost Plus Drug Company, PBC.

Nevro Corp. today announced that 24-month data from the SENZA Painful Diabetic Neuropathy (PDN) Randomized Controlled Trial (RCT).

Moderna, Inc. today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, August 3, 2023 to report its second quarter 2023 financial results, and provide a corporate update.

3Daughters announces key senior leadership appointments and the formation of a Scientific Advisory Board to support the development of its lead asset, a highly innovative and frameless intrauterine device for contraception.

Menarini Silicon Biosystems (MSB), a pioneer in liquid biopsy and single cell technologies, announced today the availability of its new CELLSEARCH CTC lab service to detect expression of the Delta-Like Ligand 3 (DLL3) protein in tumor cells circulating in the bloodstream.

Perrigo Company plc announced today that the U.S. Food and Drug Administration (FDA) approved Opill ® , a progestin-only daily oral contraceptive, for over-the-counter (OTC) use for all ages.

Sirona Biochem Corp . (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“ Sirona ”) provides the following update: Dear shareholders, We are pleased to provide an update on the progress we have made over the last months: Corporate Strategic Planning One of our communicated objectives in 2022 and the first half of 2023 was to conduct a thorough strategic review of the company.

RedShift BioAnalytics announces the launch of Aurora, the company’s latest system using ground-breaking MMS technology.

Cumulus Neuroscience (Cumulus; The Company) today announced a major research collaboration with the Universities of Bath and Bristol on development of the Fastball electroencephalogram (EEG) test, an innovative diagnostic test for earlier detection of Alzheimer’s Dementia (AD).